Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited Gross Profit Margin for the year ending March 31, 2024: 29.88%

Bafna Pharmaceuticals Limited Gross Profit Margin is 29.88% for the year ending March 31, 2024, a -11.06% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Bafna Pharmaceuticals Limited Gross Profit Margin for the year ending March 31, 2023 was 33.60%, a -15.50% change year over year.
Bafna Pharmaceuticals Limited Gross Profit Margin for the year ending March 31, 2022 was 39.76%, a 9.92% change year over year.
Bafna Pharmaceuticals Limited Gross Profit Margin for the year ending March 31, 2021 was 36.17%, a -0.55% change year over year.
Bafna Pharmaceuticals Limited Gross Profit Margin for the year ending March 31, 2020 was 36.37%, a 79.43% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years